AIM: To determine and study the relationship between adiponectin and inflammatory markers in obese, non-obese, type 2 diabetic and non-diabetic Trinidadians. METHODS: It was a cross-sectional study comprised of 133 subjects of Trinidadians. Anthropometric indices were measured and adiponectin, inflammatory marker levels, lipid profiles and glucose were measured in fasting blood samples. RESULTS: Adiponectin levels were significantly lower (P = 0.003) in diabetics (n = 60) than non diabetics (n = 73). No correlation between adiponectin and inflammatory markers was found. Adiponectin levels were negatively correlated with BMI adjusting for age and diabetic status, and gender (beta = -0.200, P = 0.020; beta = -0.235, P = 0.004). CONCLUSIONS: No correlation exists between adiponectin and inflammatory markers. Adiponectin levels are lower in type 2 diabetic Trinidadians than in non-diabetics and decreases with increasing adiposity, using BMI as the marker.
AIM: To determine and study the relationship between adiponectin and inflammatory markers in obese, non-obese, type 2 diabetic and non-diabetic Trinidadians. METHODS: It was a cross-sectional study comprised of 133 subjects of Trinidadians. Anthropometric indices were measured and adiponectin, inflammatory marker levels, lipid profiles and glucose were measured in fasting blood samples. RESULTS:Adiponectin levels were significantly lower (P = 0.003) in diabetics (n = 60) than non diabetics (n = 73). No correlation between adiponectin and inflammatory markers was found. Adiponectin levels were negatively correlated with BMI adjusting for age and diabetic status, and gender (beta = -0.200, P = 0.020; beta = -0.235, P = 0.004). CONCLUSIONS: No correlation exists between adiponectin and inflammatory markers. Adiponectin levels are lower in type 2 diabetic Trinidadians than in non-diabetics and decreases with increasing adiposity, using BMI as the marker.
Authors: Sophie N Saxton; Lauren K Toms; Robert G Aldous; Sarah B Withers; Jacqueline Ohanian; Anthony M Heagerty Journal: Cardiovasc Drugs Ther Date: 2021-03-09 Impact factor: 3.727